Cytokines, treatment of multiple sclerosis

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

Multiple sclerosis, polyunsaturated fatty acids

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

Polyunsaturated fatty acids, neurodegenerative diseases

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

Treatment of multiple sclerosis

BTG International Limited (2005) Treatment of neurodegenerative conditions. WO2005/018632/A1.

multiple sclerosis, central nervous system, neurodegeneration

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

phospholipids, treatment of multiple sclerosis

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

polyunsaturated fatty acids, treatment of multiple sclerosis

BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.

structured phospholipids, cytokines, multiple sclerosis

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

triazines, medical use

University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.

triazines, sodium channel blockers, central nervous system diseases

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.